Merck’s MRK stock has risen 30.4% this year so far compared with an increase of 4.3% for the industry. An ongoing recovery from the disruptions related to the pandemic and strong global underlying ...

Aug 1 (Reuters) - Merck KGaA (MRCG.DE), opens new tab is seeing a faster-than-expected improvement in its semiconductor materials business and is aiming to accelerate its drug development pipeline, ...

Merck has increased its dividend for 14 consecutive years. Its 10-year dividend growth rate of 5.4% is only decent. Merck increased its revenue from $39.5 billion in FY 2015 to $64.2 billion in FY ...

Vree TM for Diabetes 2.0 Helps Patients Manage Their Condition and Facilitates Communication with Healthcare Providers Merck today announced the launch of a mobile application designed to be used by ...

Merck MRK boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales.